Letrozole
Letrozole is a new oral nonsteroidal inhibitor of aromatase activity. Letrozole is used to treat advanced breast cancer in women in whom tamoxifen is failed.
Primary Characteristics
It belongs to Benzonitrile.
It is classified in Antineoplastic Agent, Aromatase Inhibitor pharmacological group.
Molecular Weight: 285.3 · Solubility in Water: insoluble · Solubility in Alcohol: slightly soluble · Non-proprietary name: Letrozole.
Pharmacokinetics
Absorption: Letrozole has an oral bioavailability is 99.9% (±16.3%).
Distribution: Letrozole has a volume of distribution is 1.9 l/kg. plasma protein binding is 60 %.
Elimination: plasma half-life is 2 days, renal excretion is 90 %.
Advertisement
Indications
Letrozole is primarily indicated in conditions like Breast cancer.
Letrozole is also indicated for secondary conditions like Advanced breast cancer in postmenopausal women.
Contraindications
None recorded.
Dosage
Letrozole's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 2.5 mg | 2.5 mg | Every 24h | PO | |
| Paediatric Dosage (20kg) | ||||
| 0 – 0 | — | — | Not applicable for this age group | |
| Neonatal Dosage (3kg) | ||||
| 0 – 0 | — | — | Not applicable in this age group | |
Drug Interactions
None recorded.
Side Effects
Letrozole in overdosage may give rise to further complications which include Thromboembolic disorder .
Letrozole is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Bone fracture, Coughing, Diarrhea, Dizziness, Dyspnea, Headache, Hot flushes, Myalgia, Nausea and vomiting, Rashes , SomnolenceX, Stevens Johnson syndrome, Vaginal dryness.
Warnings / Precautions
Interference in Pathology
Letrozole may interfere in the diagnosis of Elevations of SGPT and SGOT , Increases Serum Bilirubin .
Available Brands
Click on a strength to view available brands.
Single Ingredient
Storage Conditions
Drug Classification
- 1.8.3 — Hormones and antihormones